Researchcardiac ablationclinical trialadagio medical
Adagio Medical Publishes Feasibility Study Results
|
3.8
Adagio Medical Holdings Inc. (NASDAQ:ADGM) on February 4 announced publication of results from a US Early Feasibility Study evaluating ultralow temperature cardiac ablation (ULTC) for scar-related ventricular tachycardia. The multicenter four-site study enrolled 20 patients and reported no major adverse events at 7 or 30 days, 92.9% non-inducibility, and favorable 24-week clinical outcomes.
Scoring Rationale
Segmental clinical update with modest novelty; small 20-patient sample and limited independent validation lower impact.
Practice with real Ad Tech data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
Active Search Campaigns by BudgetEasyHigh CPC Clicks & Poor Landing PagesMediumCampaign ROAS by Attribution ModelHard
250 free problems · No credit card
See all Ad Tech problems
